Sorrento Therapeutics has been granted a patent for variant anti-OX40 antibodies that mimic the activity of OX40L, enhancing T cell clonal expansion and differentiation. The antibodies have improved binding affinity and agonistic activity compared to the wild type antibody. They specifically bind to OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, and stimulate production of cytokines. GlobalData’s report on Sorrento Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sorrento Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. Sorrento Therapeutics's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Variant anti-ox40 antibody for enhancing t cell expansion
A recently granted patent (Publication Number: US11773177B2) discloses an anti-OX40 antibody and its use in various methods for inducing proliferation and cytokine production in effector T cells. The antibody, or an antigen binding fragment thereof, specifically binds to an OX40 epitope and is characterized by a heavy chain variable domain with a specific amino acid sequence (SEQ ID NO. 9) and a light chain variable domain with another specific amino acid sequence (SEQ ID NO. 7).
The patent claims cover different aspects of the anti-OX40 antibody. Claim 1 describes the antibody or antigen binding fragment, while claim 2 specifies that the antibody is of the IgG isotype. Claim 3 encompasses various antibody formats, including Fab, Fab', F(ab')2, Fv, domain antibody, single chain antibody, diabody, triabody, and tetrabody. Claim 4 includes a polypeptide comprising the antibody or antigen-binding fragment.
The patent also discloses methods for inducing proliferation of effector T cells using the anti-OX40 antibody. Claim 6 describes a method where effector T cells are contacted with the antibody, leading to their proliferation. Claim 7 adds the step of detecting an increase in proliferation of the effector T cells. Claim 8 further includes contacting the effector T cells with CD3. Claim 9 specifies that the effector T cells are CD4+ effector T cells.
Additionally, the patent covers methods for inducing effector T cells to increase production of cytokines. Claim 10 describes a method where effector T cells are contacted with the anti-OX40 antibody, resulting in increased cytokine production. Claim 11 adds the step of detecting an increase in cytokine production by the effector T cells. Claim 12 specifies that the cytokines can include gamma-interferon, IL-2, IL-4, and tumor necrosis factor (TNF). Claim 13 includes contacting the effector T cells with CD3, and claim 14 specifies that the effector T cells are CD4+ effector T cells.
Furthermore, the patent discloses a method for inducing proliferation of effector T cells in the presence of regulatory T cells. Claim 15 describes a method where both effector T cells and regulatory T cells are contacted with the anti-OX40 antibody, leading to increased proliferation of the effector T cells. Claim 16 adds the step of detecting an increase in proliferation of the effector T cells. Claim 17 includes contacting the effector T cell and the regulatory T cell with CD3. Claim 18 specifies that the effector T cells express CD25, and claim 19 states that the effector T cells produce at least one cytokine selected from IL-2, IL-4, and INF?.
In summary, the granted patent discloses an anti-OX40 antibody and its use in various methods for inducing proliferation and cytokine production in effector T cells. The antibody specifically binds to an OX40 epitope and can be of the IgG isotype. The methods involve contacting the effector T cells with the antibody, optionally in combination with CD3, and can be applied to CD4+ effector T cells. These findings have potential implications for the development of immunotherapies targeting T cell responses.
To know more about GlobalData’s detailed insights on Sorrento Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
